Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 23458131)


Impact of preoperative therapy on patterns of recurrence in pancreatic cancer.

Papavasiliou P, Hoffman JP, Cohen SJ, Meyer JE, Watson JC, Chun YS.

HPB (Oxford). 2014 Jan;16(1):34-9. doi: 10.1111/hpb.12058. Epub 2013 Feb 20.


Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head.

Denost Q, Laurent C, Adam JP, Capdepont M, Vendrely V, Collet D, Cunha AS.

HPB (Oxford). 2013 Sep;15(9):716-23. doi: 10.1111/hpb.12039. Epub 2013 Jan 10.


Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.

Bosset JF, Calais G, Mineur L, Maingon P, Stojanovic-Rundic S, Bensadoun RJ, Bardet E, Beny A, Ollier JC, Bolla M, Marchal D, Van Laethem JL, Klein V, Giralt J, Clavère P, Glanzmann C, Cellier P, Collette L; EORTC Radiation Oncology Group.

Lancet Oncol. 2014 Feb;15(2):184-90. doi: 10.1016/S1470-2045(13)70599-0. Epub 2014 Jan 17.


Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.

McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA.

HPB (Oxford). 2010 Feb;12(1):73-9. doi: 10.1111/j.1477-2574.2009.00136.x.


Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.

Cooper AB, Holmes HM, des Bordes JK, Fogelman D, Parker NH, Lee JE, Aloia TA, Vauthey JN, Fleming JB, Katz MH.

J Am Coll Surg. 2014 Jul;219(1):111-20. doi: 10.1016/j.jamcollsurg.2014.02.023. Epub 2014 Mar 13.


Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer.

Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K.

Ann Surg. 2009 Jul;250(1):88-95. doi: 10.1097/SLA.0b013e3181ad65cc.


Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.

Tani M, Kawai M, Miyazawa M, Hirono S, Ina S, Nishioka R, Fujita Y, Uchiyama K, Yamaue H.

Langenbecks Arch Surg. 2009 Mar;394(2):249-53. doi: 10.1007/s00423-008-0296-4. Epub 2008 Mar 15.


Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).

Tachezy M, Gebauer F, Petersen C, Arnold D, Trepel M, Wegscheider K, Schafhausen P, Bockhorn M, Izbicki JR, Yekebas E.

BMC Cancer. 2014 Jun 7;14:411. doi: 10.1186/1471-2407-14-411.


Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma.

Greer SE, Pipas JM, Sutton JE, Zaki BI, Tsapakos M, Colacchio TA, Gibson JJ, Wiener DC, Ripple GH, Barth RJ Jr.

J Am Coll Surg. 2008 Mar;206(3):451-7. doi: 10.1016/j.jamcollsurg.2007.10.002. Epub 2007 Dec 27.


Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.

Breslin TM, Hess KR, Harbison DB, Jean ME, Cleary KR, Dackiw AP, Wolff RA, Abbruzzese JL, Janjan NA, Crane CH, Vauthey JN, Lee JE, Pisters PW, Evans DB.

Ann Surg Oncol. 2001 Mar;8(2):123-32.


Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial.

Golcher H, Brunner TB, Witzigmann H, Marti L, Bechstein WO, Bruns C, Jungnickel H, Schreiber S, Grabenbauer GG, Meyer T, Merkel S, Fietkau R, Hohenberger W.

Strahlenther Onkol. 2015 Jan;191(1):7-16. doi: 10.1007/s00066-014-0737-7. Epub 2014 Sep 25.


Preoperative chemoradiotherapy improves local recurrence free survival in locally advanced rectal cancer.

Tural D, Ozturk M, Selcukbiricik F, Yildiz O, Elicin O, Turna H, Guney S, Ozguroglu M.

J BUON. 2013 Apr-Jun;18(2):385-90.


The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.


Neoadjuvant-intensified treatment for rectal cancer: time to change?

Musio D, De Felice F, Bulzonetti N, Guarnaccia R, Caiazzo R, Bangrazi C, Raffetto N, Tombolini V.

World J Gastroenterol. 2013 May 28;19(20):3052-61. doi: 10.3748/wjg.v19.i20.3052.


Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy.

Turrini O, Waters JA, Schnelldorfer T, Lillemoe KD, Yiannoutsos CT, Farnell MB, Sarr MG, Schmidt CM.

HPB (Oxford). 2010 Sep;12(7):447-55. doi: 10.1111/j.1477-2574.2010.00196.x.


Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

Papalezova KT, Tyler DS, Blazer DG 3rd, Clary BM, Czito BG, Hurwitz HI, Uronis HE, Pappas TN, Willett CG, White RR.

J Surg Oncol. 2012 Jul 1;106(1):111-8. doi: 10.1002/jso.23044. Epub 2012 Feb 6.


Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.

Magnin V, Moutardier V, Giovannini MH, Lelong B, Giovannini M, Viret F, Monges G, Bardou VJ, Alzieu C, Delpero JR.

Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1300-4.


Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapy.

Tzeng CW, Fleming JB, Lee JE, Wang X, Pisters PW, Vauthey JN, Varadhachary G, Wolff RA, Katz MH.

HPB (Oxford). 2012 Jun;14(6):365-72. doi: 10.1111/j.1477-2574.2012.00445.x. Epub 2012 Feb 28.


Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status.

Mullinax JE, Hernandez JM, Toomey P, Villadolid D, Bowers C, Cooper J, Rosemurgy AS.

Am J Surg. 2012 Nov;204(5):704-8. doi: 10.1016/j.amjsurg.2012.01.016.


Adjuvant therapies in extended pancreatectomy for ductal adenocarcinoma of the pancreas.

Ishikawa O, Ohigashi H, Sasaki Y, Masao K, Kabuto T, Furukawa H, Imaoka S.

Hepatogastroenterology. 1998 May-Jun;45(21):644-50.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk